|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...3738394041424344454647...6566» |
- ||||| Nimenrix (MenACWY-TT) / Pfizer
Enrollment change: Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (clinicaltrials.gov) - Mar 26, 2014
P3, N=260, Recruiting, Sponsor: GlaxoSmithKline
N=432 --> 260
- |||| gepotidacin (GSK2140944) / GSK
Enrollment open, Gram positive: Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Mar 26, 2014
P2, N=240, Recruiting, Sponsor: GlaxoSmithKline
N=432 --> 260 Not yet recruiting --> Recruiting
- ||| Enrollment closed: Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis (clinicaltrials.gov) - Mar 25, 2014
P2, N=450, Active, not recruiting, Sponsor: NovaBay Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- erythromycin / Generic mfg., amoxicillin / Generic mfg.
Trial completion: Treatment of Antenatal Chlamydia Infection (clinicaltrials.gov) - Mar 25, 2014
P2, N=220, Completed, Sponsor: Obafemi Awolowo University Teaching Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change: HUC-PHIN: Hub Cleansing to Prevent Hub Infection (clinicaltrials.gov) - Mar 24, 2014
P=N/A, N=509, Completed, Sponsor: Rush University Medical Center
Recruiting --> Completed N=800 --> 509
- Clinical: Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological Samples for Evaluation of Correlates of TB (C-041-972) (clinicaltrials.gov) - Mar 24, 2014
P=N/A, N=3506, Not yet recruiting, Sponsor: Aeras
- | murepavadin (POL7080) / Spexis
New P2 trial: Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia (clinicaltrials.gov) - Mar 24, 2014
P2, N=25, Recruiting, Sponsor: Polyphor Ltd.
- SQ-109 / Sequella
Enrollment closed: Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design (clinicaltrials.gov) - Mar 24, 2014
P2, N=365, Active, not recruiting, Sponsor: Michael Hoelscher
N=800 --> 509 Recruiting --> Active, not recruiting
- Trial completion: HUC-PHIN: Hub Cleansing to Prevent Hub Infection (clinicaltrials.gov) - Mar 24, 2014
P=N/A, N=509, Completed, Sponsor: Rush University Medical Center
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- | Trial suspension: Costa Rica Epidemiological Study on S. Pneumoniae (clinicaltrials.gov) - Mar 23, 2014
P=N/A, N=4000, Suspended, Sponsor: Instituto de Atención Pediátrica
Enrolling by invitation --> Completed Recruiting --> Suspended
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment change: Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients (clinicaltrials.gov) - Mar 23, 2014
P1, N=25, Completed, Sponsor: Sanofi
Recruiting --> Suspended N=36 --> 25
- | efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion: Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients (clinicaltrials.gov) - Mar 23, 2014
P1, N=25, Completed, Sponsor: Sanofi
N=36 --> 25 Active, not recruiting --> Completed
- |||||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
New P3 trial: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Mar 20, 2014
P3, N=458, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- | murepavadin (POL7080) / Spexis
Enrollment open: Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia (clinicaltrials.gov) - Mar 20, 2014
P2, N=25, Recruiting, Sponsor: Polyphor Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | ceftaroline fosamil / Generic mfg.
Clinical data, Enrollment change: Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia (clinicaltrials.gov) - Mar 19, 2014
P3, N=12, Completed, Sponsor: Albany Medical College
Not yet recruiting --> Recruiting N=75 --> 12
- Trial completion: ProVIP: Probiotic Therapy for the Reversal of Bacterial Vaginosis in Pregnancy (clinicaltrials.gov) - Mar 19, 2014
P2, N=86, Completed, Sponsor: Mount Sinai Hospital, Canada
N=75 --> 12 Active, not recruiting --> Completed
- || ceftaroline fosamil / Generic mfg.
Clinical data, Trial completion: Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia (clinicaltrials.gov) - Mar 19, 2014
P3, N=12, Completed, Sponsor: Albany Medical College
Active, not recruiting --> Completed Recruiting --> Completed
- SQ-109 / Sequella
Trial withdrawal: Effects of SQ109 on QTc Interval in Healthy Subjects (clinicaltrials.gov) - Mar 19, 2014
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Not yet recruiting --> Withdrawn
- SQ-109 / Sequella
Enrollment change: Effects of SQ109 on QTc Interval in Healthy Subjects (clinicaltrials.gov) - Mar 19, 2014
P1, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Withdrawn N=48 --> 0
- | New P4 trial: RCT: Triple vs Sequential vs Concomitant Therapy H Pylori (clinicaltrials.gov) - Mar 18, 2014
P4, N=455, Recruiting, Sponsor: Changi General Hospital
- Enrollment closed: Vouchers to Promote Tdap Vaccination (clinicaltrials.gov) - Mar 17, 2014
P0, N=240, Active, not recruiting, Sponsor: Children's Hospital of Philadelphia
N=48 --> 0 Recruiting --> Active, not recruiting
- | Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
Trial completion, Combination therapy: Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (clinicaltrials.gov) - Mar 17, 2014
P3, N=284, Completed, Sponsor: Sanofi Pasteur MSD
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trumenba (meningococcal B vaccine) / Pfizer
Enrollment change: B1971042: Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (clinicaltrials.gov) - Mar 16, 2014
P2, N=13, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed N=70 --> 13
- |||||| Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Enrollment open: Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) (clinicaltrials.gov) - Mar 16, 2014
P3, N=566, Recruiting, Sponsor: Bayer
N=70 --> 13 Not yet recruiting --> Recruiting
- | Trumenba (meningococcal B vaccine) / Pfizer
Trial completion: B1971042: Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (clinicaltrials.gov) - Mar 16, 2014
P2, N=13, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Xepi (ozenoxacin) / Maruho, Cipher, Ferrer International
New P3 trial: Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo (clinicaltrials.gov) - Mar 16, 2014
P3, N=0, Not yet recruiting, Sponsor: Ferrer Internacional S.A.
- |||||||||| Adacel (tetanus toxoid/reduced diphtheria toxoid/acellular pertussis vaccine adsorbed) / Sanofi
New P3 trial: Study of SP306 Given Intramuscularly Compared to DT BIK® Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old (clinicaltrials.gov) - Mar 13, 2014
P3, N=534, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- Clinical: A Clinical Challenge Study of BCG in Healthy Volunteers (clinicaltrials.gov) - Mar 13, 2014
P=N/A, N=40, Recruiting, Sponsor: University of Oxford
- || Altabax (retapamulin) / GSK, Almirall
Enrollment change: ALTARGOPMS: ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) (clinicaltrials.gov) - Mar 12, 2014
P=N/A, N=3000, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=4500 --> 3000
- Enrollment change: PNA FISH, PCR and Gram Staining for Detection of Bacterial Vaginosis - a Comparative Clinical Study in a Danish IVF Setting (clinicaltrials.gov) - Mar 10, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: Regionshospitalet Viborg, Skive
N=4500 --> 3000 N=100 --> 150
- Enrollment change: Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil (clinicaltrials.gov) - Mar 10, 2014
P4, N=34758, Completed, Sponsor: Ataulpho de Paiva Foundation
N=100 --> 150 N=300000 --> 34758
- Clinical: Microcirculatory Impairment in Patients With Leprosy (clinicaltrials.gov) - Mar 10, 2014
P=N/A, N=20, Completed, Sponsor: Curt Treu
- Trial completion: Xpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil (clinicaltrials.gov) - Mar 10, 2014
P4, N=34758, Completed, Sponsor: Ataulpho de Paiva Foundation
N=300000 --> 34758 Not yet recruiting --> Completed
- New P2 trial: MecillinamCT: Mecillinam for Treatment of Genital Chlamydia Infection (clinicaltrials.gov) - Mar 9, 2014
P2, N=50, Not yet recruiting, Sponsor: Oslo University Hospital
- | Enrollment open: Chepetsa TB - Reducing TB Among HIV-Infected Malawians (clinicaltrials.gov) - Mar 9, 2014
P3, N=2000, Recruiting, Sponsor: Johns Hopkins University
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Enrollment open: TailoredT: Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis (clinicaltrials.gov) - Mar 7, 2014
P=N/A, N=1200, Recruiting, Sponsor: MeMed Diagnostics Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion: Interleukin-1 Trap to Treat Autoinflammatory Diseases (clinicaltrials.gov) - Mar 5, 2014
P2, N=11, Completed, Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- brilacidin (PMX-30063) / Innovation Pharma
Enrollment open: Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections (clinicaltrials.gov) - Mar 5, 2014
P2, N=215, Enrolling by invitation, Sponsor: Cellceutix Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- |||||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
Enrollment open: Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children (clinicaltrials.gov) - Mar 5, 2014
P3, N=300, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- | Ilaris (canakinumab) / Novartis
Trial completion: CONTROL FMF: Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF) (clinicaltrials.gov) - Mar 4, 2014
P2, N=15, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial termination: Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori (clinicaltrials.gov) - Mar 3, 2014
P1/2, N=33, Terminated, Sponsor: Synergy Pharmaceuticals Pte. Ltd.
Active, not recruiting --> Completed Recruiting --> Terminated; Poor efficacy (2 of 31 completing participants with H.pylori eradication)
- Enrollment change: Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori (clinicaltrials.gov) - Mar 3, 2014
P1/2, N=33, Terminated, Sponsor: Synergy Pharmaceuticals Pte. Ltd.
Recruiting --> Terminated; Poor efficacy (2 of 31 completing participants with H.pylori eradication) N=70 --> 33
- | fluconazole oral / Generic mfg.
New P4 trial: Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants (clinicaltrials.gov) - Mar 3, 2014
P4, N=80, Not yet recruiting, Sponsor: Anders Rane, MD, PhD, Senior professor
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P3 trial, Pneumococcal vaccines: Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - Mar 3, 2014
P3, N=750, Enrolling by invitation, Sponsor: SK Chemicals Co.,Ltd.
- meropenem / Generic mfg.
Trial completion: Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children (clinicaltrials.gov) - Mar 3, 2014
P4, N=30, Completed, Sponsor: Joseph Kuti
N=70 --> 33 Recruiting --> Completed
- ||| Enrollment open: Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults (clinicaltrials.gov) - Mar 3, 2014
P1, N=52, Recruiting, Sponsor: Novartis
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults. (clinicaltrials.gov) - Mar 3, 2014
P1, N=50, Recruiting, Sponsor: Novartis
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Cubicin (daptomycin) / Merck (MSD)
Trial suspension, Gram positive: Daptomycin in Pediatric Patients With Bacterial Meningitis (clinicaltrials.gov) - Mar 2, 2014
P1, N=5, Suspended, Sponsor: University Hospital Inselspital, Berne
Not yet recruiting --> Recruiting Recruiting --> Suspended
- |||||| Baxdela (delafloxacin) / Menarini, Melinta Therap
Enrollment open: Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea (clinicaltrials.gov) - Feb 26, 2014
P3, N=757, Recruiting, Sponsor: Melinta Therapeutics, Inc.
Recruiting --> Suspended Not yet recruiting --> Recruiting
- AERAS-404 / Sanofi
New P1 trial: A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults (clinicaltrials.gov) - Feb 26, 2014
P1, N=60, Completed, Sponsor: Aeras